Similar companies
Income Statement (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Gross Profit | -58M | 286.4% |
| Cost of Revenue | 58M | 1285.4% |
| Operating expense | 91M | 8.7% |
| Net Income | -136M | 264.5% |
| EBITDA | -144M | 140.5% |
Balance Sheet (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Total Assets | 2.17B | 3.4% |
| Total Liabilities | 337M | 8.7% |
| Total Equity | 1.83B | 5.3% |
| Shares Outstanding | 86M | 0.6% |
Cash Flow (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Cash from operations | -54M | 7.8% |
| Cash from financing | 11M | 37.3% |
EPS
Financial Highlights for Crispr Therapeutics in Q1 '25
Gross Profit stood at -58M, marking a -286.4% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 58M, a 1285.4% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 91M, showing a -8.7% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -136M, showing a -264.5% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -144M, showing a -140.5% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Crispr Therapeutics faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. An increase in the cost of revenue, higher than the revenue growth, suggests potential margin pressures. A decline in EBITDA signals potential operational challenges or increased costs.
